

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Enteral liquid peptide formula

INITIATION

Prerequisites (tick boxes where appropriate)

Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable
and

- Severe malabsorption
 - or**
 - Short bowel syndrome
 - or**
 - Intractable diarrhoea
 - or**
 - Biliary atresia
 - or**
 - Cholestatic liver diseases causing malabsorption
 - or**
 - Cystic fibrosis
 - or**
 - Proven fat malabsorption
 - or**
 - Severe intestinal motility disorders causing significant malabsorption
 - or**
 - Intestinal failure
- and**
- The patient is currently receiving funded amino acid formula
 - The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula

- and**
- A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable
 - or**
 - For step down from intravenous nutrition

Note: A reasonable trial is defined as a 2-4 week trial.

CONTINUATION

Prerequisites (tick boxes where appropriate)

- An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken
- and**
- The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula

I confirm that the above details are correct:

Signed: Date: